Dose response to intraventricular glial cell line-derived neurotrophic factor administration in Parkinsonian monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1396-1401

  Zhang, Zhiming ^a,b   Miyoshi, Yasuyuki ^a,b   Lapchak, Paul A ^a,d   Collins, Frank ^a,d   Hilt, Dana ^a,d   Lebel, Carl ^a,d   Kryscio, Richard ^a,c   Gash, Don M ^a,b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; DOPAMINE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GLIA CELL; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MONKEY; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; TREATMENT PLANNING;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, INTRAVENTRICULAR; MACACA MULATTA; MPTP POISONING; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0030967428     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. ARENAS, E., TRUPP, M., AKERUD, P. AND IBANEZ, C. F.: GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15: 1465-1473, 1995.
2. BANKIEWICZ, K. S., OLDFILE, E. H., CHIUEH, C. C., DOPPMAN, J. L. JACOBOWITZ, D. M. AND KOPIN, I. J.: Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39: 7-16, 1986.
3. BERGMANN, K. J., MENDOZA, M. R. AND YAHR, M. D.: Parkinson's disease and long-term levodopa therapy. Adv. Neurol. 45: 463-467, 1986.
4. 3H]Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J Pharm. 99: 167-175, 1984.
5. GASH, D. M., ZHANG, Z., CASS, W. A., OVADIA, A., SIMMERMAN, L., MARTIN, D., RUSSELL, D., COLLINS, F., HOFFER, B. J. AND GERHARDT, G. A.: Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363: 345-358, 1995.
6. GASH, D. M., ZHANG, Z., OVADIA, A., CASS, W. A., YI, A., SIMMERMAN, L., RUSSELL, D., MARTIN, D., LAPCHAK, P. A., COLLINS, F., HOFFER, B. J. AND GERHARDT, G. A.: Functional recovery in GDNF-treated parkinsonian monkeys. Nature 380: 252-255, 1996.
7. HENDERSON, C. E., PHILLIPS, H. S., POLLOCK, R. A., DAVIES, A. N., LEMEULLE, C., ARMANINI, M., SIMPSON, L. C., MOFFET, B., VANDLEN, R. A., KOLIATSOS, V. E. AND ROSENTHAL, A.: GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266: 1062-1064, 1994.
8. HOFFER, B. J., HOFFMAN, A., BOWENKAMP, K., HUETTL, P., HUDSON, J., MARTIN, D., LIN, L.-F. H. AND GERHARDT, G. A.: Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182: 107-111, 1994.
9. HORNYKIEWICZ, O.: Parkinson's disease and the adaptive capacity of the nigro-striatal dopamine system: possible neurochemical mechanisms. Adv. Neurol. 60: 140-147, 1993.
10. HORNYKIEWICZ, O. AND KISH, S. J.: Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45: 19-34, 1986.
11. HUDSON, J., GRANHOLM, A.-C., GERHARDT, G., HENRY, M. A., HOFFMAN, A., BIDDLE, P., LEELA, N. S., MACKERLOVA, L., LILE, J. D., COLLINS, F. AND HOFFER, B. J.: Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36: 425-432, 1995.
12. KISH, S. J., SHANNAK, K. AND HORNYKIEWICZ, O.: Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318: 876-880, 1988.
13. LAPCHAK, P. A., JIAO, S. S., COLLINS F. AND MILLER, P.: Glial cell line-derived neurotrophic factor: Distribution and pharmacology in the rat following a bolus intraventricular injection. Brain. Res. 747: 92-102, 1997a.
14. LAPCHAK, P. A., MILLER, P. J AND JIAO, S. S.: Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged F344 rats. Neuroscience 77: 745-752, 1997b.
15. LAPCHAK, P. A., MILLER, P. J., JIAO, S. S., ARAUJO, D. M., HILT, D. AND COLLINS F.: Biology of Glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Pakinson's disease. Neurodegeneration 5: 197-205, 1996.
16. LIN, L.-F. H., DOHERTY, D. H., LILE, J. D., BEKTESH, S. AND COLLINS, F.: GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132, 1993.
17. MIYOSHI, Y., ZHANG, Z., OVADIA, A., LAPCHAK, P. A., COLLOINS, F., HILT, D., LEBEL, C., KRYSCIO, R. AND GASH, D. M.: GDNF-Levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. (in press).
18. OPPENHEIM, R. W., HOUENOU, L. J., JOHNSON, J. E., LIN, L.-F. H., LI, L., LO, A. C., NEWSOME, A. L., PREVETTE, D. M. AND WANG, S.: Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 373: 344-346, 1995.
19. OVADIA, A., ZHANG, Z. AND GASH, D. M.: Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16: 931-937, 1995.
20. SCHOENBERG, B. S.: Descriptive epidemiology of Parkinson's disease: Disease distribution and hypothesis formulation. Adv. Neurol. 45: 277-283, 1986.
21. SMITH, R. D., ZHANG, Z., KURLAN, R., MCDERMOTT, M. AND GASH, D. M.: Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neurosci. 52: 7-16, 1993.
22. TOMAC, A., LINDQVIST, E., LIN, L.-F. H., OGREN, S. O., YOUNG, D., HOFFER, B. J. AND OLSON, L.: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339, 1995.
23. WILLIAMS, L. R., INOUYE, G., CUMMINS, V. AND PELLEYMOUNTER, M. A.: Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmacol. Exp. Ther. 277: 1140-1151, 1996.
24. YAHR, M. D.: Parkinson's disease: The L-dopa era. Adv. Neurol. 60: 11-17, 1993.